Shams ul Nisa

The GSK is advancing global healthcare and economic growth through a robust innovation pipeline, delivering breakthrough medicines while expanding its market presence over 75 countries, reports WealthPk. The company is setting new industry standards and driving sustainable impact by uniting science, technology, and talent.

GSK is accelerating its innovation efforts, investing £6.4 billion in R&D in 2024 to support a robust pipeline of 71 vaccines and medicines, including 19 in advanced stages. The company anticipates five major product approvals in 2025, including treatments for multiple myeloma, severe asthma, and urinary tract infections.

As a result, the company has driven impressive commercial growth, with Specialty Medicines experiencing a 19% sales rise, and respiratory and immunology therapies, particularly Trelegy, showing notable expansion.

GSK’s innovation pipeline is fueling strong economic growth, with a 2024 global turnover of £31.4 billion and projected sales growth of 3% to 5% in 2025. Global operating profit and earnings per share are expected to rise 6% to 8%, bolstered by new product launches.

GSK’s strategy centers on patient-focused care, accountability, and ethical practices. Its collaborative approach with healthcare professionals and communities supports the delivery of over 2.1 billion medicine packs and vaccines annually. In Pakistan, GSK has served over 200 million patients for more than seven decades, solidifying its role as the country’s leading multinational pharmaceutical firm.

GSK’s growth is underpinned by a strong commitment to sustainability and responsible business practices. In 2024, the company achieved a 12% reduction in operational carbon emissions and ranked second in the global Access to Medicine Index, showcasing its leadership in environmental and social governance. The company plans to expand access to its vaccines and medicines, including innovative new products, to reach even more people in need.

GSK Pakistan operates three advanced manufacturing facilities in Karachi, including F-268 SITE, West Wharf, and Korangi, producing over 400 million medicine and vaccine packs annually. These facilities focus on producing a wide range of specialized products, including tablets, liquids, dermatology treatments, injectables, and eye drops. Backed by an extensive distribution network, the company ensures reliable access to essential medicines across Pakistan.

GSK is set for sustained economic growth and lasting health impact with a strong pipeline, strategic market expansion, and a focus on innovation. The company's goal to improve the health of 2.5 billion people by 2030 underscores its leadership at the intersection of science, business, and social progress. GSK’s innovation pipeline continues to drive both global health advancements and economic prosperity through collaborations with partners, patients, and communities.

Credit: INP-WealthPk